AI Insight
The U.S. Food and Drug Administration has approved Rextovy (naloxone hydrochloride), an intranasal naloxone spray, for over-the-counter sale. This represents another non-prescription option for emergency treatment of opioid overdose, manufactured by Amphastar Pharmaceuticals. The approval expands access to this life-saving medication without requiring a prescription.
Why it matters
Increased over-the-counter availability of naloxone can save lives by allowing faster intervention during opioid overdoses, particularly in communities heavily affected by the opioid crisis. Removing prescription requirements reduces barriers to access for family members, first responders, and bystanders who may need to administer emergency treatment.
Understand the Science
The U.S. Food and Drug Administration has approved another over-the-counter intranasal naloxone product, Rextovy (naloxone hydrochloride), for the emergency treatment of opioid overdose. The nonprescription approval was granted to Amphastar Pharmaceuticals.
Source: FDA approves another over-the-counter naloxone nasal spray